Retatrutide 10mg
Triple-action metabolic formula for appetite and routine support.
Best For
Routine consistency and metabolic-support goals
What to Review
Compare fit, dosage, and route this formula into a simple routine before checkout.
Secure in-site checkout flow with a focused cart review before order submission
About This Formula
Retatrutide is an investigational triple-receptor agonist targeting GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors simultaneously. This triple-action profile distinguishes it from dual agonists like tirzepatide. Phase 2 clinical trials have reported significant reductions in body weight over 48 weeks, alongside improvements in glycemic markers, lipid profiles, and cardiovascular risk factors. It is currently in Phase 3 trials and is not FDA-approved for any indication.
Key Points
- Triple agonist: GLP-1, GIP, and glucagon receptor activity
- Phase 2 data showed up to 24% mean body weight reduction at 48 weeks
- Studied for improvements in HbA1c, triglycerides, and blood pressure
- Investigational compound — currently in Phase 3 clinical development
Administration
Subcutaneous injection, typically once weekly. Requires reconstitution with bacteriostatic water. High-risk tier — review qualifications and consult a healthcare professional before use.
Routine Notes
Best suited for those with a clearly defined metabolic goal and professional oversight in place. Not a starting point for casual wellness routines — review the risk tier and education pages before committing.